***Background.*** HIV is associated with dysfunctional cellular and humoral immunity. The effects of co-infection with hepatitis C virus (HCV) on immune reconstitution are controversial. The utility of monitoring B-cell lymphocyte counts in HIV patients has not been well studied. In the present study, we compare the effect of antiretroviral therapy (ART) on CD4 and B-cell counts in HIV mono-infected (HIV + /HCV-) and HCV co-infected (HIV + /HCV+) patients.

***Methods.*** Retrospective observational cohort of 160 HIV-infected patients (39 with HCV co-infection) who suppressed plasma viral load (VL) to undetectable levels within one-year of ART initiation. We reviewed baseline clinical and demographic variables, and CD4 and B-cell counts at two time points: prior to ART initiation and after 9-15 months of persistently undetectable VL (post-ART). A multiple general linear regression model was used to test for significant associations between predictor variables and change in B-cell counts after adjusting for pre-ART levels as well as covariates significant in the univariate analysis.

***Results.*** The median absolute pre- to post-ART increase in CD4 and B-cell counts did not differ significantly between the 2 groups (table). In HIV + /HCV- and HIV + /HCV+ patients, the % increase in B-cell and CD4 count were strongly correlated (Spearman\'s R 0.58 and R 0.65, respectively, P \< 0.001). In a multiple regression model adjusting for pre-ART B-cell count, HCV-co-infected patients experienced a not statistically significant 15% greater rise in B-cell counts, compared to mono-infected group (P = 0.08).

###### 

CD4 and B-cell increases after 9-15 months of persistently undetectable VL

               Parameter           HIV+/HCV-             HIV+/HCV+            P-value
  ------------ ------------------- --------------------- -------------------- ---------
  **CD4**      Absolute Δ\*        199.0 (115.0-342.0)   162.0 (79.0-237.0)   0.15
  \% Δ\*\*     98.8 (39.3-189.0)   64.6 (33.0-177.8)     0.20                 
  **B-cell**   Absolute Δ          84.3 (22.6-200.4)     90.7 (15.1-201.7)    0.98
  \% Δ         81.0 (24.6-203.8)   88.6 (5.3-233.9)      0.98                 

Median increase (IQR); cells/mL plasma; \*\*% increase from pre-ART count.

***Conclusion.*** In this cohort of patients with 9-15 months of suppressed viremia after ART initiation, HCV co-infection did not significantly influence the magnitude of reconstitution of CD4 or B cell counts. Changes in B-cell and CD4 count were strongly correlated. Our data provide support to recent guidelines against routine monitoring of B cell counts.

***Disclosures.*** **All authors:** No reported disclosures.

[^1]: **Session:** 199. HIV 4: Treatment - Outcomes, Adherence, and Toxicities

[^2]: Saturday, October 11, 2014: 12:30 PM
